Shrink the patient group, boost the efficacy: Tonix says a retro look shows promise in select PTSD group
A backwards glance at trial data — and a reshuffling of the patients involved — has reverted failure to optimism for Tonix Pharmaceuticals. At least that’s what …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
